Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs Okta, Inc. (OKTA) Price & Performance

Novavax IncTrade
Okta, Inc.Trade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Okta, Inc. — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Okta, Inc. trades at $147.43 (market cap $26.13B). The key difference: Okta, Inc. is far larger — about 19.9× Novavax Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

NVAXOKTA
Market Cap
$1.31B$26.13B
Sector
HealthTechnology
52-Week High
$11.19$154.62
52-Week Low
$6.22$62.93
Enterprise Value
$889.30M$23.95B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Okta, Inc.

Okta trades at $147.43, down 2.22% today, with a bullish technical signal from moving averages but overbought RSI readings. The company achieved GAAP profitability in 2025 with $28M net income, marking a significant turnaround from prior losses. Recent earnings beats and the acquisition of Permiso Security for AI identity threat defense highlight growth momentum. Operating cash flow surged to $750M in 2025, supporting financial flexibility.

The outlook is positive with strong analyst support (73% buy ratings) and a consensus price target of $129.71, though the current price exceeds this. Risks include high valuation multiples (P/E 108.93) and competitive pressure from Microsoft. Revenue growth to $3.0B in 2026 forecasts sustained expansion, but investor caution is warranted near technical resistance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX

About Okta, Inc.

Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.

Read more on OKTA